ABBVIE: Announces HUMIRA® (adalimumab) Global Patent License with Pfizer
AbbVie (NYSE: ABBV) announced today patent license agreements with Pfizer over its proposed biosimilar adalimumab product. Read More »
ADVANZ PHARMA: Concordia International Corp. announces name changes to ADVANZ PHARMA Corp.
Concordia International Corp. ("Concordia" or "the Company") (TSX: CXR), today announced that shareholders voted in favour of a special resolution authorizing the Company to amend its articles to change its name from Concordia International Corp. to ADVANZ PHARMA Corp. Read More »
U.S. FOOD AND DRUG ADMINISTRATION: Statement from FDA Commissioner Scott Gottlieb, M.D., on the agency’s efforts to improve drug quality through vigilant oversight of data integrity and good manufacturing practice
Ensuring the safety of our nation’s drug supply is a cornerstone of our consumer protection mission. Read More »
FIMBRION THERAPEUTICS, INC.: Fimbrion and GSK Identify Novel, Antibiotic-Sparing Development Candidate for Urinary Tract Infections
Fimbrion Therapeutics, Inc. announced that under its joint research collaboration with GSK, researchers have identified an orally available, small molecule development candidate for the treatment and prevention of urinary tract infections (UTIs). Read More »
MYLAN N.V.: Sanofi's Formulation Patents on Multibillion-Dollar Lantus® are Invalidated by U.S. Patent and Trademark Office via IPR, Announces Mylan
Mylan achieves key milestone to provide U.S. diabetes patients with more affordable generic version of Sanofi's Lantus® insulin glargine vials Read More »
VAST THERAPEUTICS: Announces Funding from Cystic Fibrosis Foundation for Further Development of BIOC51
Award Supports Advancement of BIOC51 Through Toxicology Studies in 2019 Read More »
ACORDA THERAPEUTICS, INC.: Announces FDA Approval of INBRIJA™ (levodopa inhalation powder)
.jpg){kind=tracking}
First and Only FDA-Approved Inhaled Levodopa for Intermittent Treatment of OFF Episodes in People with Parkinson’s Taking Carbidopa/Levodopa Read More »
TEVA PHARMACEUTICAL INDUSTRIES, LTD: Announces US Launch of a Generic Version of Elidel®(Pimecrolimus) Cream, 1%
.jpg){kind=tracking}
Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the launch of a generic version of Elidel®1 (pimecrolimus) Cream, 1% in the U.S. Read More »
Alerts Sign-up